{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:26:30Z","timestamp":1777857990339,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2008,8,21]],"date-time":"2008-08-21T00:00:00Z","timestamp":1219276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:p>\n                    A recently developed oral serotonergic challenge test consisting of 5-Hydroxytryptophane (5-HTP, 200 mg) combined with carbidopa (CBD, 100 mg + 50 mg) exhibited dose-related neuroendocrine responsiveness and predictable pharmacokinetics. However, its applicability is limited by nausea and vomiting. A randomized, double-blind, placebo-controlled, four-way crossover trial was performed in 12 healthy male volunteers. The 5-HTP\/CBD-challenge was combined with two oral anti-emetics (granisetron, 2 mg or domperidone, 10 mg) to investigate its reliability when side-effects are suppressed. The neuroendocrine response (serum cortisol and prolactin), the side-effect profile [Visual Analogue Scale Nausea (VAS)] and vomiting subjects per treatment were the main outcome measures. Compared to 5-HTP\/CBD\/placebo, 5-HTP\/CBD\/ granisetron had no impact on cortisol [% change with 95% confidence interval: \u22127.1% (18.9; 6.5)] or prolactin levels [\u22129.6% (\u221225.1; 9.1)]; 5-HTP\/CBD\/domperidone increased cortisol [+13.0% (\u22124.2; 33.4)], and increased prolactin extensively [+336.8% (245.7; 451.9)]. Compared to placebo, VAS Nausea increased non-significantly with granisetron [+7.6 mm (\u22121.3; 16.5)], as opposed to domperidone [+16.2 mm (7.2; 25.2)] and 5-HTP\/CBD\/placebo [+14.7 mm (5.5; 23.8)]. No subjects vomited with granisetron, compared to two subjects treated with 5-HTP\/CBD\/placebo and five subjects with domperidone. Compared with 5-HTP\/CBD\/placebo, granisetron addition decreased C\n                    <jats:sub>max<\/jats:sub>\n                    of 5-HTP statistically significantly different (from 1483 to 1272 ng\/ml) without influencing AUC\n                    <jats:sub>0\u2014 \u221e<\/jats:sub>\n                    . Addition of granisetron to the combined 5-HTP\/CBD challenge suppresses nausea and vomiting without influencing the neuroendocrine response or pharmacokinetics, enhancing its clinical applicability in future psychiatric research and drug development.\n                  <\/jats:p>","DOI":"10.1177\/0269881108094299","type":"journal-article","created":{"date-parts":[[2008,8,21]],"date-time":"2008-08-21T21:09:51Z","timestamp":1219352991000},"page":"65-72","source":"Crossref","is-referenced-by-count":9,"title":["Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron"],"prefix":"10.1177","volume":"24","author":[{"given":"GE","family":"Jacobs","sequence":"first","affiliation":[{"name":"Centre for Human Drug Research, Leiden, The Netherlands, Department of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"IMC","family":"Kamerling","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ML","family":"de Kam","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RH","family":"DeRijk","sequence":"additional","affiliation":[{"name":"Department of Medical Pharmacology, LACDR, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"van Pelt","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry, Leiden University Medical Centre, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FG","family":"Zitman","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JMA","family":"van Gerven","sequence":"additional","affiliation":[{"name":"Centre for Human Drug Research, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2008,8,21]]},"reference":[{"key":"atypb1","volume-title":"SCL-90. Handleiding bij een multidimensionele psychopathologie-indicator","author":"Arrindell, WA","year":"1986"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1974.tb02285.x"},{"key":"atypb3","first-page":"13","volume":"9","author":"Derogatis, LR","year":"1973","journal-title":"Psychopharmacol Bull"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02342.x"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/S0300-483X(00)00314-0"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)90407-W"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199808000-00007"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200204000-00012"},{"key":"atypb9","volume-title":"Structured clinical interview for DSM-IV axis I disorders","author":"Groenestijn, MAC","year":"1999"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2826.2002.00839.x"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2005.11.005"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199243030-00002"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(71)90039-6"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1016\/j.autneu.2006.07.009"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.172.1.49"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107082025"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.4.9.1563"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1016\/0166-4328(96)00097-6"}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881108094299","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0269881108094299","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:05:28Z","timestamp":1777507528000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0269881108094299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,21]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1177\/0269881108094299"],"URL":"https:\/\/doi.org\/10.1177\/0269881108094299","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,21]]}}}